Company
Rezera
Better tomorrows start with reducing chronic inflammation today.
- Business model
- B2B
- Legal name
- Rezera Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Rezera is a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 to address inflammatory drivers of cardiovascular and neurologic diseases driven by the NLRP3 inflammation pathway.
Products
- Web
- ruvonoflast
- Web
- trabzanoflast
Loading relationship preview